ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts

28 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting

25 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study

25 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments

22 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Arcutis to Host Investor Day on March 28

21 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

02 Mar 2022 04:30:00 By Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

22 Feb 2022 15:01:00 By Nasdaq GlobeNewswire

Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis

01 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners

23 Dec 2021 07:00:00 By Nasdaq GlobeNewswire